Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden

Platelets. 2009 Sep;20(6):367-75. doi: 10.1080/09537100903096676.

Abstract

Microparticles (MPs) are blebs released from cellular surfaces during activation/apoptosis. They are procoagulant, pro-inflammatory and could contribute to pathogenesis of deep venous thrombosis (DVT). This study compared the number, cellular origin and procoagulant activity of MPs on DVT patients in different clinical situations: at diagnosis (n = 9, 5F/4M; mean age = 41.11), 1-3 years after warfarin withdrawal (n = 10, 7F/3M; mean age = 32.90), associated to antiphospholipid syndrome (APS; n = 11, 9F/2M; mean age = 33.82), or asymptomatic carriers of Factor V Leiden (FVL; n = 7, 7F/0M; mean age = 34.00) vs healthy controls (CTR). The quantification and characterization were performed by flow cytometry using CD235, CD61, CD45, CD31, CD14, CD45, anti-TF and Annexin V. The plasmatic procoagulant activity was investigated by prothrombin fragment 1 + 2 (F1 + 2) determination. The MPs procoagulant activity was analyzed by D-dimer (DD2) and Thrombin Generation Test (TGT) on a healthy pool of plasmas adjusted or not by their number (10,000 MPs). The MPs percentages were not different between the groups, but absolute number was increased in patients 1-3 years after warfarin withdrawal vs CTR (P = 0.02). There was no difference of the MPs cellular origin comparing patients to controls. TGT using 10,000 MPs was lower on these patients (P = 0.01). APS patients showed a reduction of plasmatic procoagulant activity (P = 0.004), but they were under warfarin therapy. DD2 in the presence of MPs, independently of its number, was higher in patients with DVT at diagnosis (P < 0.0001). MPs of patients with spontaneous DVT at diagnosis can promote coagulation activation demonstrated by increased DD2. Even the increased MPs from patients 1-3 years after thrombotic episode generated lower amount of thrombin, they can have a protective effect by activation of Protein C anticoagulant pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiphospholipid Syndrome / blood
  • Antiphospholipid Syndrome / genetics
  • Antiphospholipid Syndrome / pathology*
  • Blood Coagulation Tests
  • Case-Control Studies
  • Factor V / genetics
  • Factor V / metabolism*
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Flow Cytometry
  • Humans
  • Lipoproteins / metabolism
  • Male
  • Particle Size
  • Substance Withdrawal Syndrome / blood
  • Substance Withdrawal Syndrome / pathology
  • Thrombin / genetics
  • Thrombin / metabolism
  • Thrombosis / blood
  • Thrombosis / genetics
  • Thrombosis / pathology
  • Venous Thrombosis / blood
  • Venous Thrombosis / genetics
  • Venous Thrombosis / pathology*
  • Warfarin / administration & dosage

Substances

  • Fibrin Fibrinogen Degradation Products
  • Lipoproteins
  • factor V Leiden
  • fibrin fragment D
  • Warfarin
  • Factor V
  • Thrombin